Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Anesta Fentanyl Oralet promotion and distribution should become less restrictive -- FDA committee.

Executive Summary

FENTANYL ORALET PROMO, DISTRIBUTION SHOULD BECOME LESS RESTRICTIVE, FDA's Anesthetic & Life Support Drugs Advisory Committee recommended Dec. 12. The committee unanimously agreed that promotion of the Abbott/Anesta narcotic analgesic (oral transmucosal fentanyl) should be allowed to extend to journal advertising and that distribution should go through the typical channels of wholesalers and distribution centers. "I personally can't see any benefit in putting such a restriction on the sponsor" for distribution and promotion, committee Chairman John Downs, MD, University of South Florida College of Medicine, said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel